Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivo Bio TechBOM:511509 +0.69%60 EV-to-EBITDA is 5.20 as of Sep. 06, 2026, which is 2% above its 10-year median of 5.09. GuruFocus rates BOM:511509 with a GF Score™ of 60/100 and a GF Value™ of ₹30.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 399 Biotechnology companies, Vivo Bio Tech ranks better than 68.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vivo Bio Tech's enterprise value is ₹1,079.3 Mil.
Vivo Bio Tech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹207.7 Mil. Therefore, Vivo Bio Tech's EV-to-EBITDA for today is 5.20.
The historical rank and industry rank for Vivo Bio Tech's EV-to-EBITDA or its related term are showing as below:
BOM:511509'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.81 Med: 5.09 Max: 14.87
Current: 5.2
During the past 13 years, the highest EV-to-EBITDA of Vivo Bio Tech was 14.87. The lowest was 1.81. And the median was 5.09.
BOM:511509's EV-to-EBITDA is ranked better than 68.92% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs BOM:511509: 5.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vivo Bio Tech (BOM:511509) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivo Bio Tech's PE Ratio (TTM) for today is calculated as:
Vivo Bio Tech's share price for today is ₹18.92.
Vivo Bio Tech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vivo Bio Tech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:511509 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vivo Bio Tech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivo Bio Tech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivo Bio Tech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vivo Bio Tech's EV-to-EBITDA falls into.
Vivo Bio Tech's current Enterprise Value is ₹1,079.3 Mil.
Vivo Bio Tech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹207.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivo Bio Tech (BOM:511509) has a EV-to-EBITDA of 5.20 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vivo Bio Tech. This is near median its historical median of 5.09. Over the past decade, Vivo Bio Tech's EV-to-EBITDA has ranged from 1.81 to 14.87. According to the industry distribution chart, Vivo Bio Tech ranks #124 out of 399 companies in the Biotechnology industry, placing it in the top 31.1%.
Is Vivo Bio Tech's EV-to-EBITDA too high?
Vivo Bio Tech's current EV-to-EBITDA of 5.20 is near median its 10-year median of 5.09. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 14.87. The Biotechnology industry median EV-to-EBITDA is 13.70. Vivo Bio Tech's value of 5.20 is 62% below this industry median. Based on the distribution chart, Vivo Bio Tech ranks #124 out of 399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vivo Bio Tech has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivo Bio Tech's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivo Bio Tech ranks #124 out of 399 companies for EV-to-EBITDA. This puts Vivo Bio Tech in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. Vivo Bio Tech's value of 5.20 is 62% below this benchmark. Historically, Vivo Bio Tech's own EV-to-EBITDA has ranged from 1.81 to 14.87 over the past decade. While the company's 10-year median is 5.09 vs. the industry median of 13.70, Vivo Bio Tech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivo Bio Tech's current EV-to-EBITDA of 5.20 is 62% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vivo Bio Tech. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivo Bio Tech's current EV-to-EBITDA is 5.20, which is near median its own 10-year median of 5.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivo Bio Tech stock overvalued right now?
Based on GuruFocus' analysis, Vivo Bio Tech (BOM:511509) is currently considered Possible Value Trap. The stock's GF Value™ is ₹30.03, compared to a current price of ₹18.92 — trading 37% below its estimated fair value. The current EV-to-EBITDA is 5.20, which is near median its 10-year median of 5.09 and 62% below the Biotechnology industry median of 13.70. Vivo Bio Tech's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vivo Bio Tech (BOM:511509), the current EV-to-EBITDA is 5.20 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivo Bio Tech (BOM:511509) Overvalued in 2026?
Based on GuruFocus' analysis, Vivo Bio Tech stock appears to be undervalued.
The current stock price of ₹18.92 is trading 37% below its estimated GF Value™ of ₹30.03.
GuruFocus considers Vivo Bio Tech to be Possible Value Trap.
Key valuation signals for BOM:511509:
EV-to-EBITDA: 5.20 (near median its 10-year median of 5.09)
GF Value™: ₹30.03 vs. price of ₹18.92 (37% below fair value)
Industry Position: 62% below the Biotechnology median (#124 of 399)
No single metric tells the full story. See the BOM:511509 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivo Bio Tech Ltd offers drug development and discovery services to pharmaceutical and biotech companies. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. It offers services in the areas of pharmacology, toxicology, pathology, analytical chemistry, lab animal diagnostics, custom model generation, custom breeding, surgical models, and molecular biology.
60GF Score
Get the complete analysis for BOM:511509
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:511509 has been successfully added to your 
